These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 16932553)
21. [Dystroglycan linkage and muscular dystrophy]. Shimizu T Rinsho Shinkeigaku; 2002 Nov; 42(11):1091-4. PubMed ID: 12784674 [TBL] [Abstract][Full Text] [Related]
22. Developmental defects in a zebrafish model for muscular dystrophies associated with the loss of fukutin-related protein (FKRP). Thornhill P; Bassett D; Lochmüller H; Bushby K; Straub V Brain; 2008 Jun; 131(Pt 6):1551-61. PubMed ID: 18477595 [TBL] [Abstract][Full Text] [Related]
23. [Pathomechanism and therapeutic strategy of Fukuyama congenital muscular dystrophy and related disorders]. Toda T Rinsho Shinkeigaku; 2009 Nov; 49(11):859-62. PubMed ID: 20030231 [TBL] [Abstract][Full Text] [Related]
24. Glycobiology of α-dystroglycan and muscular dystrophy. Endo T J Biochem; 2015 Jan; 157(1):1-12. PubMed ID: 25381372 [TBL] [Abstract][Full Text] [Related]
25. Exclusion of WWP1 mutations in a cohort of dystroglycanopathy patients. Godfrey C; Clement E; Abbs S; Muntoni F Muscle Nerve; 2011 Sep; 44(3):388-92. PubMed ID: 21996799 [TBL] [Abstract][Full Text] [Related]
26. Muscular dystrophies due to glycosylation defects. Muntoni F; Torelli S; Brockington M Neurotherapeutics; 2008 Oct; 5(4):627-32. PubMed ID: 19019316 [TBL] [Abstract][Full Text] [Related]
27. [Recent advances in congenital muscular dystrophy research]. Nonaka I No To Hattatsu; 2005 Mar; 37(2):115-21. PubMed ID: 15773323 [TBL] [Abstract][Full Text] [Related]
32. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression. Kanagawa M; Yu CC; Ito C; Fukada S; Hozoji-Inada M; Chiyo T; Kuga A; Matsuo M; Sato K; Yamaguchi M; Ito T; Ohtsuka Y; Katanosaka Y; Miyagoe-Suzuki Y; Naruse K; Kobayashi K; Okada T; Takeda S; Toda T Hum Mol Genet; 2013 Aug; 22(15):3003-15. PubMed ID: 23562821 [TBL] [Abstract][Full Text] [Related]
33. The modulation of skeletal muscle glycosylation as a potential therapeutic intervention in muscular dystrophies. Brockington M; Muntoni F Acta Myol; 2005 Dec; 24(3):217-21. PubMed ID: 16629056 [TBL] [Abstract][Full Text] [Related]
34. FKRP mutations cause congenital muscular dystrophy 1C and limb-girdle muscular dystrophy 2I in Asian patients. Awano H; Saito Y; Shimizu M; Sekiguchi K; Niijima S; Matsuo M; Maegaki Y; Izumi I; Kikuchi C; Ishibashi M; Okazaki T; Komaki H; Iijima K; Nishino I J Clin Neurosci; 2021 Oct; 92():215-221. PubMed ID: 34509255 [TBL] [Abstract][Full Text] [Related]
35. Glyc-O-genetics of Walker-Warburg syndrome. van Reeuwijk J; Brunner HG; van Bokhoven H Clin Genet; 2005 Apr; 67(4):281-9. PubMed ID: 15733261 [TBL] [Abstract][Full Text] [Related]
36. Dystroglycan glycosylation and muscular dystrophy. Moore CJ; Hewitt JE Glycoconj J; 2009 Apr; 26(3):349-57. PubMed ID: 18773291 [TBL] [Abstract][Full Text] [Related]
37. TRAPPC11 and GOSR2 mutations associate with hypoglycosylation of α-dystroglycan and muscular dystrophy. Larson AA; Baker PR; Milev MP; Press CA; Sokol RJ; Cox MO; Lekostaj JK; Stence AA; Bossler AD; Mueller JM; Prematilake K; Tadjo TF; Williams CA; Sacher M; Moore SA Skelet Muscle; 2018 May; 8(1):17. PubMed ID: 29855340 [TBL] [Abstract][Full Text] [Related]